Numerion Labs

Atomwise is an AI drug discovery company founded in 2012 in San Francisco by Abraham Heifets and Izhar Wallach. The company pioneered the use of convolutional neural networks for molecular recognition with its AtomNet platform, which has screened over 3 trillion synthesizable compounds across more than 600 disease targets.

Atomwise has partnerships with Sanofi, Eli Lilly, and Bayer spanning oncology, common diseases, and orphan conditions, and a Y Combinator alum.

The company has raised approximately $174 million across multiple rounds, including a $123 million Series B co-led by B Capital Group and Sanabil Investments.